Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Hepatol.

Title: Journal of hepatology

Publisher: Elsevier BV

ISSN (Electronic): 1600-0641

ISSN (Print): 0168-8278

Publication date (Electronic): Dec 2016

Volume: 65

Issue: 6

Affiliations

[1 ] Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: jorge.marrero@utsouthwestern.edu.

[2 ] Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.

[3 ] Medical Oncology and Translational Research, University of California, San Francisco, CA, USA.

[4 ] Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.

[5 ] University Henri Poincaré by University of Lorraine, Nancy, France.

[6 ] Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

[7 ] Policlínica Metropolitana, Caracas, Venezuela.

[8 ] Kyorin University School of Medicine, Mitaka, Tokyo, Japan.

[9 ] Vascular and Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

[10 ] Hospital Angeles Clínica Londres, Mexico City, Mexico.

[11 ] University Hospital of Larissa, Larissa, Greece.

[12 ] Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.

[13 ] Virginia Commonwealth University Medical Center, Richmond, VA, USA.

[14 ] The Catholic University of Korea, Seoul, Republic of Korea.

[15 ] Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Inc., Montville, NJ, USA.

[16 ] Clinical Statistics, Bayer HealthCare Pharmaceuticals, Inc., Montville, NJ, USA.

[17 ] Global Medical Affairs and Pharmacovigilance, Bayer HealthCare Pharmaceuticals, Inc., Berlin, Germany.

[18 ] Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy.

Article

Publisher Item ID: S0168-8278(16)30346-4

DOI: 10.1016/j.jhep.2016.07.020

PubMed ID: 27469901

SO-VID: c65110e2-8392-4ac6-8595-bff4824f1d01

History

Keywords: Sorafenib,GIDEON,HCC,Hepatocellular carcinoma,Nexavar,Child-Pugh

Data availability:

Keywords: Sorafenib, GIDEON, HCC, Hepatocellular carcinoma, Nexavar, Child-Pugh

Comments

Comment on this article

scite_

Cited by 146

Molecular therapies and precision medicine for hepatocellular carcinoma
Authors: Richard Finn, Josep Llovet, Robert Montal …
Hepatocellular carcinoma
Authors: Arndt Vogel, Tim Meyer, Gonzalo Sapisochin …
Targeted therapy for hepatocellular carcinoma
Authors: Ao Huang, Xin-Rong Yang, Wen-Yuan Chung …

See all cited by

- Version 1